Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumour antigen
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumour antigen. / Rasmussen, A B; Zocca, M-B; Bonefeld, C M; von Essen, M; Lauritsen, J P; Tomra, S; Odum, N; Geisler, C.
In: Scandinavian Journal of Immunology, Vol. 59, No. 2, 2004, p. 220-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumour antigen
AU - Rasmussen, A B
AU - Zocca, M-B
AU - Bonefeld, C M
AU - von Essen, M
AU - Lauritsen, J P
AU - Tomra, S
AU - Odum, N
AU - Geisler, C
N1 - Keywords: Amino Acid Sequence; Antigen Presentation; Antigens, Neoplasm; Blotting, Western; Cancer Vaccines; Cell Line; Cysteine Endopeptidases; Cytotoxicity Tests, Immunologic; Epitopes; Humans; Melanoma; Molecular Sequence Data; Multienzyme Complexes; Neoplasm Proteins; Plasmids; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Repetitive Sequences, Nucleic Acid; T-Lymphocytes; Transfection; Vaccines, DNA
PY - 2004
Y1 - 2004
N2 - Melanoma antigen recognized by T cell 1 (MART-1) is regarded as a candidate peptide for vaccination against malignant melanoma, and it is of importance to develop strategies to improve the vaccine-elicited T-cell activation towards MART-1. T-cell activation is, among other determinants, dependent on the density of specific major histocompatibility complex-peptide complexes on the surface of the antigen-presenting cell. In this study, we explored the cell-surface presentation of a substituted MART-1 peptide encoded by transfected minigenes. We investigated the potential of proteasomal targeting compared to non-proteasomal targeting of the epitope to increase its cell-surface presentation. Furthermore, we explored the potential of incorporating multiple minigenes instead of one to increase cell-surface presentation. We show that both proteasomal targeting and repetition of the minigene increase cell-surface presentation of the epitope and propose both these approaches as potential strategies in DNA vaccines to increase MART-1-specific T-cell activation.
AB - Melanoma antigen recognized by T cell 1 (MART-1) is regarded as a candidate peptide for vaccination against malignant melanoma, and it is of importance to develop strategies to improve the vaccine-elicited T-cell activation towards MART-1. T-cell activation is, among other determinants, dependent on the density of specific major histocompatibility complex-peptide complexes on the surface of the antigen-presenting cell. In this study, we explored the cell-surface presentation of a substituted MART-1 peptide encoded by transfected minigenes. We investigated the potential of proteasomal targeting compared to non-proteasomal targeting of the epitope to increase its cell-surface presentation. Furthermore, we explored the potential of incorporating multiple minigenes instead of one to increase cell-surface presentation. We show that both proteasomal targeting and repetition of the minigene increase cell-surface presentation of the epitope and propose both these approaches as potential strategies in DNA vaccines to increase MART-1-specific T-cell activation.
M3 - Journal article
C2 - 14871300
VL - 59
SP - 220
EP - 227
JO - Scandinavian Journal of Immunology, Supplement
JF - Scandinavian Journal of Immunology, Supplement
SN - 0301-6323
IS - 2
ER -
ID: 8544376